INDEPENDENT NEWS

ArborGen faces faster route to commercialisation in US

Published: Fri 16 Mar 2012 02:08 PM
ArborGen faces faster route to commercialisation in streamlined US approval process
By Paul McBeth
March 16 (BusinessDesk) – Forestry biotech company ArborGen, which counts NZX-listed Rubicon as a major shareholder, may be on a quicker route to taking one of its products to market after US officials trimmed the timeline in the approval process of biotechnology products.
The US Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) has outlined new processes to determine whether biotech products should be approved for commercial use, cutting the time to 13 to 16 months from an average three years per petition previously.
That means ArborGen could get its cold-tolerant eucalyptus product to market sooner than previously expected, provided it secures all the appropriate approvals.
“These process improvements announced by APHIS represent a significant improvement to the regulatory approval process previously in place, and these changes will be welcomed by the wider biotechnology community,” chief executive Andrew Baum, who was only appointed to lead the company this week, said in a statement. “The new process should achieve faster petition determinations without foregoing any of the rigour of APHIS’s environment assessment process.”
ArborGen wants to bring genetically-modified eucalyptus trees to market to enable production of the hardwood for pulp and biofuel in managed plantations in the south-eastern United States. The company has been selling varietal pine seedlings since 2006.
An early approval would be a fillip to the forestry biotech company, which was forced to shelve plans for an initial public offering last year as US financial markets struggled to revive in the wake of the global financial crisis, several years ago.
ArborGen’s shareholders Rubicon, International Paper and MeadWestvaco will have to source new funding to pursue a float, and may need to stump up more cash, tap private capital or seek new bank finance.
Shares in Rubicon climbed 5.4 percent to 39 cents in trading today.
(BusinessDesk)
BusinessDesk
Independent, Trustworthy New Zealand Business News
The Wellington-based BusinessDesk team provides a daily news feed for a serious business audience.
Contact BusinessDesk
Email:

Next in Business, Science, and Tech

Services lead GDP growth
By: Statistics New Zealand
Letter to Immigration Minister From Early Harvesting Growers
By: One Plus One
Scientists discover one of world’s oldest bird species
By: Canterbury Museum
Helping regions fill skills shortages and Kiwis come first
By: New Zealand Government
Report: Govt Inquiry into Auckland Fuel Supply Disruption
By: Inquiry into The Auckland Fuel Supply Disruption
NZ economy grows 0.5% in June quarter, beating expectations
By: BusinessDesk
Don’t blame President Trump for slowing economy
By: New Zealand National Party
Labour's big government economic policies continue to fail
By: ACT New Zealand
Kiwi economic growth slows. We need fiscal caffeination
By: Kiwibank
Weakening economic growth shows need for tax cuts
By: New Zealand Taxpayers' Union
Employers pen open letter to Minister in ‘desperation’
By: New Zealand National Party
Dismissive Minister out of touch with reality
By: ACT New Zealand
Labour issues in booming sector
By: Bayleys
Migrant Workers Association criticises work visa overhaul
By: RNZ
More detail needed on migrant worker policy
By: BusinessDesk
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media